Veracyte, Inc. (VCYT) Earnings
Veracyte, Inc. is expected to report next earnings on August 5, 2026 (in NaN days), with a consensus EPS estimate of $0.44. VCYT has beaten EPS estimates in 11 of its last 12 reported quarters (average surprise +43.5% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 5, 2026 | $0.34 | $0.52 | +52.9% | $139M | +6.7% |
| Feb 25, 2026 | $0.41 | $0.51 | +23.9% | $141M | +3.6% |
| Aug 6, 2025 | $0.31 | $0.44 | +41.9% | $130M | +4.7% |
| May 7, 2025 | $0.20 | $0.31 | +55.0% | $114M | +3.2% |
| Feb 22, 2024 | $-0.07 | $-0.04 | +42.9% | $98M | +6.8% |
| May 4, 2023 | $-0.14 | $-0.11 | +21.4% | $82M | +8.7% |
| Feb 22, 2023 | $-0.15 | $-0.05 | +66.7% | $80M | +8.6% |
| Nov 2, 2022 | $-0.24 | $-0.12 | +50.0% | $76M | +13.8% |
| Aug 2, 2022 | $-0.21 | $-0.13 | +38.1% | $73M | +7.0% |
| May 3, 2022 | $-0.23 | $-0.20 | +13.0% | $68M | +9.5% |
| Feb 28, 2022 | $-0.14 | $-0.15 | -7.1% | $67M | +7.7% |
| Jul 29, 2021 | $-0.25 | $-0.13 | +48.0% | $55M | +0.0% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 5, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
• Mark Stapley mentioned strong double-digit revenue and volume growth in Q1, exceeded profitability expectations, and advanced key catalysts. • Discussed Decipher's consistent growth over 20% quarter after quarter, strong performance in Q1 with 24% volume growth, traction in advanced disease, upcoming trial results, and enhancements in clinical offerings. • Talked about Affirma's 12% volume growth, transition to V2 transcriptome workflow improving no result rate, expanding clinical evidence, and real-world impact. • Highlighted Procigna LDT as a major upcoming launch with significant market opportunity and upcoming Optima trial results, and TrueMRD as a whole genome sequence-based MRD platform with planned launch in MIBC and broader applications. • Welcomed new executives to support growth.
Guidance
• Raised full-year total revenue guidance to $582 million to $592 million, representing 13 to 14% year-over-year growth. • Expected testing revenue growth of 16 to 18% excluding new tests, with Decipher revenue growth of approximately 20% and Affirma revenue growth in high single-digit to low double-digit range. • Increased full-year adjusted EBITDA guidance to greater than 26%.
Segment performance
In the first quarter, Decipher delivered approximately 28,000 tests with 24% year-over-year volume growth. Revenue growth was strong. Affirma delivered approximately 17,200 tests with 12% year-over-year volume growth. Procigna LDT and TrueMRD are upcoming product launches. Decipher's revenue growth is expected to be approximately 20%, Affirma's revenue growth is in the high single-digit to low double-digit range. Decipher contributes significantly to revenue with its strong growth and extensive clinical evidence, Affirma also contributes with its improving operational performance and expanding clinical evidence.
Analyst Q&A
Q: Puneet Sudha asked about no result rate improvement and ceiling.
A: Mark Stapley talked about transition to new workflow and Rebecca Chambers discussed financial impact and assumptions.
Q: Tycho Peterson asked about momentum in testing revenue and Decipher's competitive mode.
A: Mark Stapley and John Light discussed new product launches, ramp, and Decipher's competitive strategy.
Q: Doug Schenkel asked about Decipher's multi-year growth sustainability and Optima's ASCO readout.
A: Mark Stapley and John Light discussed Decipher's growth drivers and Optima's requirements.
Q: Subbu Nambi asked about Decipher's volume, ASPs and TrueMRD's next indication.
A: Rebecca Chambers discussed Decipher's trends and Mark Stapley discussed TrueMRD's strategic planning.
Q: Mason Carrico asked about ProSigna LDT and Decipher's volume impact from weather.
A: John Light and Mark Stapley discussed ProSigna LDT's publication and Decipher's volume impact.
Q: Kyle Mixon asked about capital allocation and M&A.
A: Mark Stapley discussed capital allocation philosophy and M&A considerations.